How medicines are managed during targeted radioligand cancer treatment
Development and Evaluation of Clinical Radiopharmacy in the Pharmaceutical Management of Patients Treated With Targeted Radionuclide Therapy (TRT) Within Nuclear Medicine Departments
This project tracks how pharmacists and nuclear medicine teams manage medications and provide pharmaceutical advice for adults receiving targeted radioligand treatments like Lutathera and Pluvicto.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 3 sites (Bron and 2 other locations) |
| Trial ID | NCT07389512 on ClinicalTrials.gov |
What this trial studies
This is an observational, multicenter database collecting information on pharmaceutical validation and any pharmaceutical interventions made for adults receiving targeted radionuclide therapy (TRT). It includes patients at first TRT course and those who receive a pharmaceutical intervention for subsequent TRT courses, while excluding minors and patients without a relevant pharmaceutical intervention. Data collection will document medication reconciliation, dosing, timing, safety checks, and types and outcomes of pharmaceutical interventions across participating nuclear medicine departments. The aim is to describe current practices and identify patterns that could inform safer, more consistent medication management in TRT.
Who should consider this trial
Good fit: Adult patients treated in participating nuclear medicine departments who receive pharmaceutical validation for their first TRT or who have a pharmaceutical intervention for any TRT course are eligible.
Not a fit: Minors and patients who do not receive a pharmaceutical intervention or who are treated outside the participating centers are not included and therefore would not directly benefit from the database findings.
Why it matters
Potential benefit: If successful, this work could reduce medication errors and improve the safety and consistency of drug use during targeted radioligand therapy.
How similar studies have performed: While therapeutic agents like Lutathera and Pluvicto have shown clear clinical benefits, formal multicenter registries focused specifically on pharmaceutical interventions in TRT are limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All adult patients treated in nuclear medicine with pharmaceutical validation for a first Targeted Radionuclide Therapy (TRT) will be included in the database. * All patients for whom a pharmaceutical intervention (PI) has been made, whether for a first or subsequent TRT. Exclusion Criteria: * Minor patient * Patient without a pharmaceutical intervention for a treatment other than the first TRT course
Where this trial is running
Bron and 2 other locations
- Hospices Civils de Lyon — Bron, France (Recruiting)
- CGFL Dijon — Dijon, France (Not_yet_recruiting)
- Centre Hospitalier Universitaire de Lille — Lille, France (Not_yet_recruiting)
Study contacts
- Study coordinator: Sarah CHAIB, PharmD
- Email: Sarah.chaib@chu-lyon.fr
- Phone: + 33 (0)4 27 85 54 14
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.